224 related articles for article (PubMed ID: 30235247)
1. Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections.
Tschudin-Sutter S; Fosse N; Frei R; Widmer AF
PLoS One; 2018; 13(9):e0203295. PubMed ID: 30235247
[TBL] [Abstract][Full Text] [Related]
2. Development of a combination antibiogram for Pseudomonas aeruginosa bacteremia in an oncology population.
Smith ZR; Tajchman SK; Dee BM; Bruno JJ; Qiao W; Tverdek FP
J Oncol Pharm Pract; 2016 Jun; 22(3):409-15. PubMed ID: 25956419
[TBL] [Abstract][Full Text] [Related]
3. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
[TBL] [Abstract][Full Text] [Related]
4. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.
Bliziotis IA; Petrosillo N; Michalopoulos A; Samonis G; Falagas ME
PLoS One; 2011; 6(10):e26470. PubMed ID: 22046290
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.
Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH
Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.
Recio R; Mancheño M; Viedma E; Villa J; Orellana MÁ; Lora-Tamayo J; Chaves F
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767719
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
9. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort.
Peña C; Suarez C; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Oliver A; Martínez-Martínez L;
Clin Infect Dis; 2013 Jul; 57(2):208-16. PubMed ID: 23580739
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
Chamot E; Boffi El Amari E; Rohner P; Van Delden C
Antimicrob Agents Chemother; 2003 Sep; 47(9):2756-64. PubMed ID: 12936970
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of death with recurrent Pseudomonas aeruginosa bacteremia.
McCarthy KL; Paterson DL
Diagn Microbiol Infect Dis; 2017 Jun; 88(2):152-157. PubMed ID: 28366610
[TBL] [Abstract][Full Text] [Related]
12. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia.
Park SY; Park HJ; Moon SM; Park KH; Chong YP; Kim MN; Kim SH; Lee SO; Kim YS; Woo JH; Choi SH
BMC Infect Dis; 2012 Nov; 12():308. PubMed ID: 23157735
[TBL] [Abstract][Full Text] [Related]
13. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species.
Rahal JJ
Clin Infect Dis; 2006 Sep; 43 Suppl 2():S95-9. PubMed ID: 16894522
[TBL] [Abstract][Full Text] [Related]
14. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.
Kim YJ; Jun YH; Kim YR; Park KG; Park YJ; Kang JY; Kim SI
BMC Infect Dis; 2014 Mar; 14():161. PubMed ID: 24655422
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
[TBL] [Abstract][Full Text] [Related]
17. Impact of Pseudomonas aeruginosa bacteraemia in a tertiary hospital: Mortality and prognostic factors.
Callejas-Díaz A; Fernández-Pérez C; Ramos-Martínez A; Múñez-Rubio E; Sánchez-Romero I; Vargas Núñez JA
Med Clin (Barc); 2019 Feb; 152(3):83-89. PubMed ID: 29885868
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa bloodstream infections: how should we treat them?
van Delden C
Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S71-5. PubMed ID: 17698326
[TBL] [Abstract][Full Text] [Related]
19. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.
Peña C; Cabot G; Gómez-Zorrilla S; Zamorano L; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez-López F; Tubau F; Martínez-Martínez L; Oliver A;
Clin Infect Dis; 2015 Feb; 60(4):539-48. PubMed ID: 25378459
[TBL] [Abstract][Full Text] [Related]
20. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa.
Osmon S; Ward S; Fraser VJ; Kollef MH
Chest; 2004 Feb; 125(2):607-16. PubMed ID: 14769745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
